  Objective: To evaluate the relationship between coronavirus disease 2019
(COVID-19) diagnosis with SARS-CoV-2 variant B.1.1.7 (also known as Variant of
Concern 202012/01) and the risk of hospitalisation compared to diagnosis with
wildtype SARS-CoV-2 variants.
  Design: Retrospective cohort, analysed using stratified Cox regression.
  Setting: Community-based SARS-CoV-2 testing in England, individually linked
with hospitalisation data.
  Participants: 839,278 laboratory-confirmed COVID-19 patients, of whom 36,233
had been hospitalised within 14 days, tested between 23rd November 2020 and
31st January 2021 and analysed at a laboratory with an available TaqPath assay
that enables assessment of S-gene target failure (SGTF). SGTF is a proxy test
for the B.1.1.7 variant. Patient data were stratified by age, sex, ethnicity,
deprivation, region of residence, and date of positive test.
  Main outcome measures: Hospitalisation between 1 and 14 days after the first
positive SARS-CoV-2 test.
  Results: 27,710 of 592,409 SGTF patients (4.7%) and 8,523 of 246,869 non-SGTF
patients (3.5%) had been hospitalised within 1-14 days. The stratum-adjusted
hazard ratio (HR) of hospitalisation was 1.52 (95% confidence interval [CI]
1.47 to 1.57) for COVID-19 patients infected with SGTF variants, compared to
those infected with non-SGTF variants. The effect was modified by age
(P<0.001), with HRs of 0.93-1.21 for SGTF compared to non-SGTF patients below
age 20 years, 1.29 in those aged 20-29, and 1.45-1.65 in age groups 30 years or
older.
  Conclusions: The results suggest that the risk of hospitalisation is higher
for individuals infected with the B.1.1.7 variant compared to wildtype
SARS-CoV-2, likely reflecting a more severe disease. The higher severity may be
specific to adults above the age of 30.
